A Phase 2 Study of Darolutamide in Combination With Leuprolide Acetate in Hormone-Therapy Naive Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
Latest Information Update: 30 May 2025
At a glance
- Drugs Darolutamide (Primary) ; Leuprorelin (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
Most Recent Events
- 17 Jan 2025 Planned number of patients changed from 20 to 21.
- 11 Oct 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 11 Oct 2023 to 9 Jan 2024.
- 13 Jul 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 13 Jul 2023 to 11 Oct 2023.